Holen Sie sich die Stockscreener-App
31.85
1.76%
-0.61
Handel nachbörslich:
31.84
-0.01
-0.03%
Schlusskurs vom Vortag:
$32.46
Offen:
$32.9
24-Stunden-Volumen:
235.31K
Relative Volume:
0.44
Marktkapitalisierung:
$891.70M
Einnahmen:
$17.16M
Nettoeinkommen (Verlust:
$-163.62M
KGV:
-5.2385
EPS:
-6.08
Netto-Cashflow:
$-121.61M
1W Leistung:
+6.76%
1M Leistung:
+36.28%
6M Leistung:
+78.56%
1J Leistung:
-8.20%
1-Tages-Spanne:
$31.73
$33.08
1-Wochen-Bereich:
$30.27
$33.97
52-Wochen-Spanne:
$12.21
$36.54
Anaptysbio Inc Stock (ANAB) Company Profile
Firmenname
Anaptysbio Inc
Sektor
Branche
Telefon
858-362-6295
Adresse
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Vergleichen Sie ANAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
31.85 | 908.00M | 17.16M | -163.62M | -121.61M | -6.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-07-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-19 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-03-12 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-02-26 | Eingeleitet | BTIG Research | Buy |
| 2024-02-21 | Eingeleitet | Stifel | Buy |
| 2024-02-16 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-06 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-13 | Herabstufung | Truist | Buy → Hold |
| 2022-09-01 | Eingeleitet | Raymond James | Outperform |
| 2022-03-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-06-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-03-16 | Hochstufung | Truist | Hold → Buy |
| 2021-03-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-10-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Herabstufung | Jefferies | Buy → Hold |
| 2019-11-08 | Herabstufung | SunTrust | Buy → Hold |
| 2019-11-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-04-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Bestätigt | Stifel | Buy |
| 2018-03-06 | Bestätigt | Stifel | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2018-01-23 | Bestätigt | Credit Suisse | Outperform |
| 2017-11-15 | Eingeleitet | SunTrust | Buy |
| 2017-11-09 | Eingeleitet | Jefferies | Buy |
| 2017-10-11 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
Barclays Initiates Coverage on AnaptysBio (NASDAQ:ANAB) - MarketBeat
AnaptysBio stock price target raised to $72 from $57 at Piper Sandler - Investing.com
How AnaptysBio Inc. stock reacts to job market dataQuarterly Portfolio Report & Expert Approved Momentum Ideas - newser.com
Is AnaptysBio Inc. stock positioned well for digital economyMarket Risk Analysis & Growth Focused Entry Reports - newser.com
Rosnilimab phase 2b rheumatoid arthritis data to be presented at ACR - Investing.com Nigeria
Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025 - MarketScreener
Why AnaptysBio Inc. stock could outperform in 2025July 2025 Reactions & Technical Pattern Alert System - newser.com
Should you wait for a breakout in AnaptysBio Inc.Weekly Gains Report & Verified Momentum Stock Alerts - newser.com
AnaptysBio Announces Late-Breaking Presentation of Phase 2b Trial Data for Rosnilimab in Rheumatoid Arthritis at ACR Convergence 2025 - Quiver Quantitative
Anaptys Announces Late-Breaking Oral Presentation of - GlobeNewswire
AnaptysBio to present rosnilimab rheumatoid arthritis data at ACR meeting - StreetInsider
6‑Month JAK‑like Efficacy: Anaptys' Rosnilimab Phase 2b Accepted for ACR Late‑Breaking Oral Presentation - Stock Titan
Barclays Initiates Coverage on AnaptysBio (ANAB) with Overweight Rating | ANAB Stock News - GuruFocus
Can AnaptysBio Inc. stock beat market expectations this quarterJuly 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
Barclays Initiates AnaptysBio at Overweight With $78 Price Target - MarketScreener
AnaptysBio Inc. stock prediction for this weekQuarterly Portfolio Report & Expert Approved Momentum Ideas - newser.com
Barclays initiates AnaptysBio stock with Overweight rating on rosnilimab potential - Investing.com Canada
What drives AnaptysBio Inc stock priceMarket Depth Overview & Small Investment Capital Tips - earlytimes.in
How moving averages guide AnaptysBio Inc. tradingGold Moves & Risk Managed Investment Signals - newser.com
Q3 EPS Estimates for AnaptysBio Lifted by Leerink Partnrs - MarketBeat
Can AnaptysBio Inc. (AN6) stock resist broad market declinesWeekly Stock Recap & Reliable Intraday Trade Alerts - newser.com
Will AnaptysBio Inc. (AN6) stock outperform benchmarks2025 Top Decliners & Free Verified High Yield Trade Plans - newser.com
AnaptysBio splits operations into two companies - MSN
AnaptysBio's (ANAB) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
AnaptysBio, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
HighMark Wealth Management LLC Raises Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
Leerink Partnrs Decreases Earnings Estimates for AnaptysBio - MarketBeat
Custom strategy builders for tracking AnaptysBio Inc.Market Sentiment Report & Growth Focused Stock Reports - newser.com
Is AnaptysBio Inc. reversing from oversold territoryWeekly Trade Review & Daily Chart Pattern Signals - newser.com
Applying sector rotation models to AnaptysBio Inc.2025 Bull vs Bear & Reliable Price Breakout Signals - newser.com
Chart overlay techniques for tracking AnaptysBio Inc.July 2025 Short Interest & Safe Capital Growth Stock Tips - newser.com
Is AnaptysBio Inc. (AN6) stock good for long term investingEarnings Miss & Breakout Confirmation Alerts - newser.com
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.9%Time to Sell? - MarketBeat
HC Wainwright Analysts Cut Earnings Estimates for AnaptysBio - MarketBeat
Biggest stock movers today: UUUU, FLY, and more - MSN
AnaptysBio (NASDAQ:ANAB) Trading 8.9% Higher After Analyst Upgrade - Defense World
AnaptysBio, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
AnaptysBio (NASDAQ:ANAB) Shares Up 8.9% on Analyst Upgrade - MarketBeat
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 - Sahm
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $59.00 at HC Wainwright - Defense World
AnaptysBio (NASDAQ:ANAB) Shares Gap Up on Analyst Upgrade - Defense World
A house dividing: Anaptysbio wants separate pipeline, royalty firms - BioWorld MedTech
AnaptysBio Announces Business Separation Plans - The Globe and Mail
Finanzdaten der Anaptysbio Inc-Aktie (ANAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anaptysbio Inc-Aktie (ANAB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER |
Sep 30 '25 |
Sale |
29.00 |
8,240 |
238,960 |
9,088 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):